What is Bendrofluazide used for?

Bendrofluazide is indicated for Hypertensive disorder.

Who makes Bendrofluazide?

Bendrofluazide is developed by Boehringer Ingelheim.

What development phase is Bendrofluazide in?

Bendrofluazide is FDA-approved (marketed).

What are the side effects of Bendrofluazide?

Common side effects include Ischemic colitis, Mesenteric arterial thrombosis, Pemphigoid rash, Hypertensive reaction in patients with pheochromocytoma, Sleep disturbances, Peyronies disease.

Last reviewed 2026-04-19 · How we verify

Bendrofluazide

Boehringer Ingelheim · FDA-approved active Small molecule

At a glance

Generic name	Bendrofluazide
Sponsor	Boehringer Ingelheim
Target	Calcium-activated potassium channel subunit alpha-1, Carbonic anhydrase 1, Carbonic anhydrase 2
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	FDA-approved

Approved indications

Hypertensive disorder

Common side effects

Ischemic colitis
Mesenteric arterial thrombosis
Pemphigoid rash
Hypertensive reaction in patients with pheochromocytoma
Sleep disturbances
Peyronies disease
Pancreatitis
Sialadenitis
Jaundice (intrahepatic cholestatic jaundice)
Hepatitis
Gastric irritation
Abdominal bloating

Key clinical trials

A Randomised, Parallel-group, Double-blind, Double-dummy Study to Compare the Effects of Lacidipine Versus Bendrofluazide on Markers of Platelet Activation and Haemorheological Factors in Hypertensive Patients (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Bendrofluazide CI brief — competitive landscape report
Bendrofluazide updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI